

Debabrata Mukherjee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4156922/publications.pdf>

Version: 2024-02-01

378
papers

34,181
citations

13827

67
h-index

3903

177
g-index

391
all docs

391
docs citations

391
times ranked

29019
citing authors

#	ARTICLE	IF	CITATIONS
1	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2016, 37, 267-315.	1.0	5,890
2	2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2014, 64, e139-e228.	1.2	2,746
3	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2011, 58, e44-e122.	1.2	2,027
4	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. <i>Circulation</i> , 2011, 124, e574-651.	1.6	1,946
5	2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1082-1115.	1.2	1,232
6	2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention, 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Dis. <i>Circulation</i> , 2016, 134, e123-55.	1.6	1,069
7	2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: Executive Summary. <i>Circulation</i> , 2014, 130, 2354-2394.	1.6	938
8	2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes. <i>Circulation</i> , 2014, 130, e344-426.	1.6	928
9	2012 ACCF/AATS/SCAI/STS Expert Consensus Document on Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1200-1254.	1.2	706
10	2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1235-1250.	1.2	684
11	Thrombolysis for Pulmonary Embolism and Risk of All-Cause Mortality, Major Bleeding, and Intracranial Hemorrhage. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 2414.	3.8	602
12	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. <i>Circulation</i> , 2011, 124, 2574-2609.	1.6	500
13	Acute Intramural Hematoma of the Aorta. <i>Circulation</i> , 2005, 111, 1063-1070.	1.6	457
14	2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2645-2687.	1.2	424
15	2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. <i>Circulation</i> , 2016, 133, 1135-1147.	1.6	403
16	ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1502-1517.	1.2	390
17	2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain. <i>Journal of the American College of Cardiology</i> , 2021, 78, e187-e285.	1.2	336
18	Meta-Analysis of the Relation of Body Mass Index to All-Cause and Cardiovascular Mortality and Hospitalization in Patients With Chronic Heart Failure. <i>American Journal of Cardiology</i> , 2015, 115, 1428-1434.	0.7	333

#	ARTICLE	IF	CITATIONS
19	2021 AHA/ACC/AASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i> , 2021, 144, e368-e454.	1.6	319
20	Impact of Combination Evidence-Based Medical Therapy on Mortality in Patients With Acute Coronary Syndromes. <i>Circulation</i> , 2004, 109, 745-749.	1.6	287
21	2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 152, 1243-1275.	0.4	249
22	ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 Expert Consensus Document on Coronary Computed Tomographic Angiography. <i>Circulation</i> , 2010, 121, 2509-2543.	1.6	247
23	ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 Expert Consensus Document on Coronary Computed Tomographic Angiography. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2663-2699.	1.2	244
24	Benefits of β blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. <i>BMJ</i> , The, 2013, 346, f55-f55.	3.0	232
25	Peripheral Arterial Disease in Patients With End-Stage Renal Disease. <i>Circulation</i> , 2006, 114, 1914-1922.	1.6	229
26	Magnesium hydridotriphenylborate [Mg(thf) ₆][HBPh ₃] ₂ : a versatile hydroboration catalyst. <i>Chemical Communications</i> , 2016, 52, 13155-13158.	2.2	212
27	Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes. <i>Diabetes Care</i> , 2010, 33, 1395-1402.	4.3	211
28	Lack of Benefit From Intravenous Platelet Glycoprotein IIb/IIIa Receptor Inhibition as Adjunctive Treatment for Percutaneous Interventions of Aortocoronary Bypass Grafts. <i>Circulation</i> , 2002, 106, 3063-3067.	1.6	201
29	Direct myocardial revascularization and angiogenesis—how many patients might be eligible?. <i>American Journal of Cardiology</i> , 1999, 84, 598-600.	0.7	199
30	Diabetic cardiomyopathy - A comprehensive updated review. <i>Progress in Cardiovascular Diseases</i> , 2019, 62, 315-326.	1.6	197
31	Association of Blood Transfusion With Increased Mortality in Myocardial Infarction. <i>JAMA Internal Medicine</i> , 2013, 173, 132.	2.6	196
32	Temporal Trends and Outcomes of Patients Undergoing Percutaneous Coronary Interventions for Cardiogenic Shock in the Setting of Acute Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 341-351.	1.1	194
33	Mitral valve surgery in patients with severe left ventricular dysfunction. <i>European Journal of Cardio-thoracic Surgery</i> , 2000, 17, 213-221.	0.6	176
34	A systematic review and meta-analysis of geographic differences in comorbidities and associated severity and mortality among individuals with COVID-19. <i>Scientific Reports</i> , 2021, 11, 8562.	1.6	175
35	Magnesium-catalyzed hydroboration of esters: evidence for a new zwitterionic mechanism. <i>Chemical Science</i> , 2014, 5, 959-964.	3.7	171
36	Alkali Metal Hydridotriphenylborates [(L)M][HBPh ₃] (M = Li, Na, K): Chemoselective Catalysts for Carbonyl and CO ₂ Hydroboration. <i>Journal of the American Chemical Society</i> , 2016, 138, 10790-10793.	6.6	171

#	ARTICLE	IF	CITATIONS
37	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary. Catheterization and Cardiovascular Interventions, 2012, 79, 453-495.	0.7	157
38	Liver Abnormalities in Cardiac Diseases and Heart Failure. International Journal of Angiology, 2011, 20, 135-142.	0.2	156
39	Effect of Clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. American Journal of Cardiology, 2001, 88, 672-674.	0.7	144
40	Patients undergoing infrainguinal bypass to treat atherosclerotic vascular disease are underprescribed cardioprotective medications: effect on graft patency, limb salvage, and mortality. Journal of Vascular Surgery, 2004, 39, 357-365.	0.6	142
41	ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. American Journal of Gastroenterology, 2008, 103, 2890-2907.	0.2	137
42	Ten-fold augmentation of endothelial uptake of vascular endothelial growth factor with ultrasound after systemic administration. Journal of the American College of Cardiology, 2000, 35, 1678-1686.	1.2	127
43	ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. Journal of the American Society of Hypertension, 2011, 5, 259-352.	2.3	125
44	Missed Opportunities to Treat Atherosclerosis in Patients Undergoing Peripheral Vascular Interventions. Circulation, 2002, 106, 1909-1912.	1.6	123
45	Impact of Prior Peripheral Arterial Disease and Stroke on Outcomes of Acute Coronary Syndromes and Effect of Evidence-Based Therapies (from the Global Registry of Acute Coronary Events). American Journal of Cardiology, 2007, 100, 1-6.	0.7	122
46	Magnesium-Catalyzed Mild Reduction of Tertiary and Secondary Amides to Amines. ACS Catalysis, 2015, 5, 4219-4226.	5.5	122
47	Carotid Artery Stenting Versus Endarterectomy for Stroke Prevention. Journal of the American College of Cardiology, 2017, 69, 2266-2275.	1.2	122
48	Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. Biochemical Pharmacology, 2002, 63, 817-821.	2.0	118
49	2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. Journal of the American College of Cardiology, 2011, 58, 2550-2583.	1.2	114
50	Peripheral arterial disease: Epidemiology, natural history, diagnosis and treatment. International Journal of Angiology, 2007, 16, 36-36.	0.2	107
51	2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. Journal of Thoracic and Cardiovascular Surgery, 2012, 144, e29-e84.	0.4	107
52	2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2021, 144, e368-e454.	1.6	99
53	2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. Catheterization and Cardiovascular Interventions, 2013, 82, E266-355.	0.7	97
54	Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes. Journal of the American College of Cardiology, 2010, 55, 2878-2886.	1.2	96

#	ARTICLE	IF	CITATIONS
55	Pharmacologic Rate versus Rhythm Control Strategies in Atrial Fibrillation: An Updated Comprehensive Review and Meta-Analysis. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2013, 36, 122-133.	0.5	90
56	Elevated leukocyte count and adverse hospital events in patients with acute coronary syndromes: findings from the Global Registry of Acute Coronary Events (GRACE). <i>American Heart Journal</i> , 2004, 147, 42-48.	1.2	89
57	Comparison of Results of Carotid Stenting Followed by Open Heart Surgery Versus Combined Carotid Endarterectomy and Open Heart Surgery (Coronary Bypass With or Without Another Procedure). <i>American Journal of Cardiology</i> , 2005, 96, 519-523.	0.7	89
58	Relationship of Body Mass Index With Total Mortality, Cardiovascular Mortality, and Myocardial Infarction After Coronary Revascularization: Evidence From a Meta-analysis. <i>Mayo Clinic Proceedings</i> , 2014, 89, 1080-1100.	1.4	88
59	Molecular Magnesium Hydrides. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 1458-1473.	7.2	86
60	2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: An update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 1001-1019.	0.7	85
61	Hydrido Complexes of Calcium: A New Family of Molecular Alkaline-Earth Metal Compounds. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 9590-9602.	7.2	85
62	Early intravenous beta-blockers in patients with acute coronary syndrome? A meta-analysis of randomized trials. <i>International Journal of Cardiology</i> , 2013, 168, 915-921.	0.8	84
63	Potential Impact of the HIPAA Privacy Rule on Data Collection in a Registry of Patients With Acute Coronary Syndrome. <i>Archives of Internal Medicine</i> , 2005, 165, 1125.	4.3	79
64	Association of peripheral artery disease with treatment and outcomes in acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). <i>American Heart Journal</i> , 2006, 151, 1123-1128.	1.2	78
65	Endovascular therapy for acute ischaemic stroke: a systematic review and meta-analysis of randomized trials. <i>European Heart Journal</i> , 2015, 36, 2373-2380.	1.0	70
66	Chemoselective Reduction of Tertiary Amides to Amines Catalyzed by Triphenylborane. <i>Angewandte Chemie - International Edition</i> , 2016, 55, 13326-13329.	7.2	70
67	Long-term cardiovascular mortality after radiotherapy for breast cancer: A systematic review and meta-analysis. <i>Clinical Cardiology</i> , 2017, 40, 73-81.	0.7	69
68	Prognostic implication of troponin I elevation after percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2003, 91, 1272-1274.	0.7	67
69	ACC 2015 Core Cardiovascular Training Statement (COCATS 4) (Revision of COCATS 3). <i>Journal of the American College of Cardiology</i> , 2015, 65, 1721-1723.	1.2	67
70	Risk of major bleeding in different indications for new oral anticoagulants: Insights from a meta-analysis of approved dosages from 50 randomized trials. <i>International Journal of Cardiology</i> , 2015, 179, 279-287.	0.8	67
71	Role of Niacin in Current Clinical Practice: A Systematic Review. <i>American Journal of Medicine</i> , 2017, 130, 173-187.	0.6	66
72	2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2021, 78, 2218-2261.	1.2	66

#	ARTICLE	IF	CITATIONS
73	Novel Oral Anticoagulants in Patients With Renal Insufficiency: A Meta-analysis of Randomized Trials. Canadian Journal of Cardiology, 2014, 30, 888-897.	0.8	65
74	Carotid artery intimal-medial thickness: Indicator of atherosclerotic burden and response to risk factor modification. American Heart Journal, 2002, 144, 753-759.	1.2	65
75	New Oral Anticoagulants Are Not Superior to Warfarin in Secondary Prevention of Stroke or Transient Ischemic Attacks, but Lower the Risk of Intracranial Bleeding: Insights from a Meta-Analysis and Indirect Treatment Comparisons. PLoS ONE, 2013, 8, e77694.	1.1	65
76	Alteration of Cardiac Collagen Phenotypes in Hypertensive Hypertrophy: Role of Blood Pressure. Journal of Molecular and Cellular Cardiology, 1993, 25, 185-196.	0.9	64
77	Selective Metal-Free Hydrosilylation of CO ₂ Catalyzed by Triphenylborane in Highly Polar, Aprotic Solvents. Chemistry - A European Journal, 2016, 22, 7730-7733.	1.7	63
78	Increased asymmetric dimethylarginine and endothelin 1 levels in secondary Raynaud's phenomenon: Implications for vascular dysfunction and progression of disease. Arthritis and Rheumatism, 2003, 48, 1992-2000.	6.7	62
79	2012 ACCF/AATS/SCAI/STS Expert Consensus Document on Transcatheter Aortic Valve Replacement. Annals of Thoracic Surgery, 2012, 93, 1340-1395.	0.7	62
80	Drug-Eluting Stents Versus Bare-Metal Stents in Saphenous Vein Graft Interventions. JACC: Cardiovascular Interventions, 2010, 3, 1262-1273.	1.1	60
81	Perioperative Cardiac Assessment for Noncardiac Surgery. Circulation, 2003, 107, 2771-2774.	1.6	59
82	Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials. International Journal of Cardiology, 2017, 228, 352-358.	0.8	59
83	Carotid artery stenting vs. endarterectomy. European Heart Journal, 2009, 30, 2693-2704.	1.0	58
84	The Nature of the Heavy Alkaline Earth Metal-Hydrogen Bond: Synthesis, Structure, and Reactivity of a Cationic Strontium Hydride Cluster. Journal of the American Chemical Society, 2018, 140, 3403-3411.	6.6	58
85	Risk factors for premature coronary artery disease and determinants of adverse outcomes after revascularization in patients ≥40 years old. American Journal of Cardiology, 2003, 92, 1465-1467.	0.7	56
86	Clinical outcome of a cohort of patients eligible for therapeutic angiogenesis or transmyocardial revascularization. American Heart Journal, 2001, 142, 72-74.	1.2	55
87	Conversion of a Zinc Disilazide to a Zinc Hydride Mediated by LiCl. Journal of the American Chemical Society, 2010, 132, 7582-7583.	6.6	52
88	Management of Transplant Renal Artery Stenosis. Angiology, 2011, 62, 219-224.	0.8	52
89	Prognostic Value of Transient and Sustained Increase in In-Hospital Creatinine on Outcomes of Patients Admitted With Acute Coronary Syndrome. American Journal of Cardiology, 2007, 99, 939-942.	0.7	51
90	ACCF/ACR/AHA/NASCI/SAIP/SCAI/SCCT 2010 Expert Consensus Document on Coronary Computed Tomographic Angiography. Catheterization and Cardiovascular Interventions, 2010, 76, E1-42.	0.7	51

#	ARTICLE	IF	CITATIONS
91	Risk factors for intracranial haemorrhage in patients with pulmonary embolism treated with thrombolytic therapy Development of the PE-CH Score. <i>Thrombosis and Haemostasis</i> , 2017, 117, 246-251.	1.8	51
92	Treatment Discontinuations With New Oral Agents for Long-term Anticoagulation: Insights From a Meta-analysis of 18 Randomized Trials Including 101,801 Patients. <i>Mayo Clinic Proceedings</i> , 2014, 89, 896-907.	1.4	50
93	Risk of Atrial Fibrillation With Use of Oral and Intravenous Bisphosphonates. <i>American Journal of Cardiology</i> , 2014, 113, 1815-1821.	0.7	50
94	Effects of cilostazol in patients with Raynaud's syndrome. <i>American Journal of Cardiology</i> , 2003, 92, 1310-1315.	0.7	49
95	Role of PPAR- α Agonist Thiazolidinediones in Treatment of Pre-Diabetic and Diabetic Individuals: A Cardiovascular Perspective. <i>Current Drug Targets Cardiovascular & Haematological Disorders</i> , 2005, 5, 377-386.	2.0	49
96	Remarkably Robust Monomeric Alkylperoxyzinc Compounds from Tris(oxazolonyl)boratozinc Alkyls and O_2 . <i>Journal of the American Chemical Society</i> , 2012, 134, 13018-13026.	6.6	48
97	Ligand Influence on Carbonyl Hydroboration Catalysis by Alkali Metal Hydridotriphenylborates [(L)M][HBPh ₃] (M=Li, Na, K). <i>Chemistry - A European Journal</i> , 2017, 23, 14292-14298.	1.7	48
98	Cardiac Overexpression of Myotrophin Triggers Myocardial Hypertrophy and Heart Failure in Transgenic Mice. <i>Journal of Biological Chemistry</i> , 2004, 279, 20422-20434.	1.6	47
99	2012 ACCF/AATS/SCAI/STS Expert Consensus Document on Transcatheter Aortic Valve Replacement. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 1023-1082.	0.7	46
100	Prognostic Implications of Creatine Kinase-MB Elevation After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 474-480.	1.4	45
101	Hybrid coronary revascularization versus coronary artery bypass grafting in patients with multivessel coronary artery disease: A meta-analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 203-212.	0.7	45
102	Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: Results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). <i>American Heart Journal</i> , 2002, 144, 995-1002.	1.2	44
103	Rivaroxaban and risk of myocardial infarction. <i>Coronary Artery Disease</i> , 2013, 24, 628-635.	0.3	44
104	Efficacy and Safety of New Oral Anticoagulants for Extended Treatment of Venous Thromboembolism: Systematic Review and Meta-Analyses of Randomized Controlled Trials. <i>Drugs</i> , 2013, 73, 1171-1182.	4.9	42
105	Timing and Route of Amiodarone for Prevention of Postoperative Atrial Fibrillation after Cardiac Surgery: A Network Regression Meta-analysis. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2013, 36, 1017-1023.	0.5	42
106	SCAI/AATS/ACC/STS Operator and Institutional Requirements for Transcatheter Valve Repair and Replacement. Part II. Mitral Valve. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1515-1526.	1.2	42
107	Critical and Acute Limb Ischemia. <i>Angiology</i> , 2014, 65, 137-146.	0.8	41
108	Outcomes of Saphenous Vein Graft Intervention With and Without Embolic Protection Device. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	41

#	ARTICLE	IF	CITATIONS
109	Aortic Dissection—An Update. <i>Current Problems in Cardiology</i> , 2005, 30, 287-325.	1.1	40
110	Peripheral and cerebrovascular atherosclerotic disease in diabetes mellitus. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2009, 23, 335-345.	2.2	39
111	Contemporary management of concomitant carotid and coronary artery disease. <i>Heart</i> , 2011, 97, 175-180.	1.2	39
112	Predictors, Trends, and Outcomes (Among Older Patients ≥65 Years of Age) Associated With Beta-Blocker Use in Patients With Stable Angina Undergoing Elective Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1639-1648.	1.1	39
113	Implementation of the ACC/AHA Guidelines for Preoperative Cardiac Risk Assessment in a General Medicine Preoperative Clinic: Improving Efficiency and Preserving Outcomes. <i>Cardiology</i> , 2005, 103, 24-29.	0.6	38
114	Eplerenone Is Not Superior to Older and Less Expensive Aldosterone Antagonists. <i>American Journal of Medicine</i> , 2012, 125, 817-825.	0.6	37
115	Implications of Periaortic Hematoma in Patients With Acute Aortic Dissection (from the International Tj ETQq1 1 0,784314 rgBT /Overl 0.7 36	0.7	36
116	Effect of Intensive Versus Standard Blood Glucose Control in Patients With Type 2 Diabetes Mellitus in Different Regions of the World: Systematic Review and Meta-analysis of Randomized Controlled Trials. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	36
117	Feasibility of simultaneous bilateral carotid artery stenting. <i>Catheterization and Cardiovascular Interventions</i> , 2004, 61, 437-442.	0.7	35
118	Meta-Analysis of Cardiovascular Outcomes With Dronedronone in Patients With Atrial Fibrillation or Heart Failure. <i>American Journal of Cardiology</i> , 2012, 110, 607-613.	0.7	35
119	Me ₆ TREN-Supported Alkali Metal Hydridotriphenylborates [(LM)[HBPh ₃] (M =) Tj ETQq1,1 0.784314 rgBT /C 1.1 35	1.1	35
120	Development of a multicenter peripheral arterial interventional database: The PVD-QI2. <i>American Heart Journal</i> , 2005, 149, 1003-1008.	1.2	34
121	Outcome of Multivessel Coronary Intervention in the Contemporary Percutaneous Revascularization Era. <i>American Journal of Cardiology</i> , 2006, 97, 1585-1590.	0.7	34
122	Zinc hydridotriphenylborates supported by a neutral macrocyclic polyamine. <i>Dalton Transactions</i> , 2017, 46, 6183-6186.	1.6	34
123	Peroxisome proliferator-activated receptor Î³ agonists for the Prevention of Adverse events following percutaneous coronary Revascularization—results of the PPAR Study. <i>American Heart Journal</i> , 2007, 154, 137-143.	1.2	31
124	Developing an Action Plan for Patient Radiation Safety in Adult Cardiovascular Medicine. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1833-1847.	1.2	31
125	Comparing newer oral anti-platelets prasugrel and ticagrelor in reduction of ischemic events-evidence from a network meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 223-232.	1.0	31
126	Myocardial Infarction With Nonobstructive Coronary Arteries: A Call for Individualized Treatment. <i>Journal of the American Heart Association</i> , 2019, 8, e013361.	1.6	31

#	ARTICLE	IF	CITATIONS
127	An Updated Review on Myocardial Bridging. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1169-1179.	0.3	31
128	Improvement in Right Ventricular Systolic Function After Surgical Correction of Isolated Tricuspid Regurgitation. <i>Journal of the American Society of Echocardiography</i> , 2000, 13, 650-654.	1.2	30
129	Interrelationships with Metabolic Syndrome, Obesity and Cardiovascular Risk. <i>Current Vascular Pharmacology</i> , 2016, 14, 415-425.	0.8	30
130	Meta-Analysis of Global Left Ventricular Function Comparing Multidetector Computed Tomography With Cardiac Magnetic Resonance Imaging. <i>American Journal of Cardiology</i> , 2014, 113, 731-738.	0.7	29
131	Drug-eluting stents in patients with end-stage renal disease: Meta-analysis and systematic review of the literature. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 76, 942-948.	0.7	28
132	Pharmacogenomics in cardiovascular diseases. <i>Progress in Cardiovascular Diseases</i> , 2002, 44, 479-498.	1.6	27
133	Remote ischemic preconditioning in patients undergoing cardiovascular surgery: Evidence from a meta-analysis of randomized controlled trials. <i>International Journal of Cardiology</i> , 2016, 221, 34-41.	0.8	26
134	Polypharmacy in Cardiovascular Medicine: Problems and Promises!. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2017, 15, 31-39.	0.4	26
135	Comparison of outcomes in acute coronary syndrome in patients receiving statins within 24 hours of onset versus at later times. <i>American Journal of Cardiology</i> , 2004, 94, 1166-1168.	0.7	25
136	Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up. <i>European Heart Journal</i> , 2005, 26, 2524-2528.	1.0	25
137	SCAI/AATS/ACC/STS Operator and Institutional Requirements for Transcatheter Valve Repair and Replacement, Part III: Pulmonic Valve. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2556-2563.	1.2	25
138	Epidemiology and Adverse Consequences of Hookah/Waterpipe Use: A Systematic Review. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2019, 17, 82-93.	0.4	25
139	Renal artery end-diastolic velocity and renal artery resistance index as predictors of outcome after renal stenting. <i>American Journal of Cardiology</i> , 2001, 88, 1064-1066.	0.7	24
140	Cardiovascular Complications of HIV Infection and Treatment. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2013, 11, 58-66.	0.4	24
141	Uninterrupted New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Ablation of Atrial Fibrillation: A Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2016, 32, 814-823.	0.8	24
142	Carotid brachytherapy for in-stent restenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2003, 58, 86-92.	0.7	23
143	Effect of Statin Use in Patients With Acute Coronary Syndromes and a Serum Low-Density Lipoprotein ≥ 80 mg/dl. <i>American Journal of Cardiology</i> , 2005, 96, 1491-1493.	0.7	23
144	COCATS 4 Task Force 1: Training in Ambulatory, Consultative, and Longitudinal Cardiovascular Care. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1734-1753.	1.2	23

#	ARTICLE	IF	CITATIONS
145	Ring-opening of cyclic ethers by aluminum hydridotriphenylborate. <i>Chemical Communications</i> , 2017, 53, 3493-3496.	2.2	23
146	MTHFR A1298C polymorphism is associated with cardiovascular risk in end stage renal disease in North Indians. <i>Molecular and Cellular Biochemistry</i> , 2008, 308, 43-50.	1.4	22
147	Coronary, Peripheral and Cerebrovascular Disease: a Complex Relationship. <i>Herz</i> , 2008, 33, 475-480.	0.4	22
148	HIV-1 Env Glycoprotein Phenotype along with Immune Activation Determines CD4 T Cell Loss in HIV Patients. <i>Journal of Immunology</i> , 2016, 196, 1768-1779.	0.4	22
149	Cationic magnesium hydride [MgH] ⁺ stabilized by an NNNN-type macrocycle. <i>Chemical Communications</i> , 2019, 55, 3199-3202.	2.2	22
150	Divergent reaction pathways of tris(oxazolonyl)borato zinc and magnesium silyl compounds. <i>Chemical Communications</i> , 2013, 49, 4334-4336.	2.2	21
151	Meta-Analysis of the Relation of Baseline Right Ventricular Function to Response to Cardiac Resynchronization Therapy. <i>American Journal of Cardiology</i> , 2016, 117, 1315-1321.	0.7	21
152	A Masked Cuprous Hydride as a Catalyst for Carbonyl Hydrosilylation in Aqueous Solutions. <i>Angewandte Chemie - International Edition</i> , 2019, 58, 1818-1822.	7.2	21
153	Women, the menopause, hormone replacement therapy and coronary heart disease. <i>Current Opinion in Cardiology</i> , 2015, 30, 432-438.	0.8	20
154	Cardiac Trauma. <i>Angiology</i> , 2016, 67, 896-901.	0.8	20
155	Device Thrombosis with Bioresorbable Scaffolds. <i>New England Journal of Medicine</i> , 2017, 376, 2388-2389.	13.9	20
156	Prognostic significance of an elevated creatine kinase in the absence of an elevated troponin I during an acute coronary syndrome. <i>American Journal of Cardiology</i> , 2003, 92, 1442-1444.	0.7	19
157	Long-term prognostic implication of extracardiac vascular disease in patients undergoing percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2003, 92, 964-966.	0.7	19
158	Basic cerebral anatomy for the carotid interventionalist: The intracranial and extracranial vessels. <i>Catheterization and Cardiovascular Interventions</i> , 2006, 68, 104-111.	0.7	19
159	CCR5 promoter activity correlates with HIV disease progression by regulating CCR5 cell surface expression and CD4 T cell apoptosis. <i>Scientific Reports</i> , 2017, 7, 232.	1.6	19
160	Heparin-induced thrombocytopenia and cardiovascular diseases. <i>American Heart Journal</i> , 2006, 152, 19-26.	1.2	18
161	The Importance of Early Diagnosis and Treatment in Peripheral Arterial Disease: Insights from the PARTNERS and REACH Registries. <i>Current Vascular Pharmacology</i> , 2010, 8, 293-300.	0.8	18
162	Safety and efficacy of Bivalirudin with Glycoprotein IIb/IIIa for high-risk percutaneous coronary intervention. <i>Indian Heart Journal</i> , 2012, 64, 444-448.	0.2	18

#	ARTICLE	IF	CITATIONS
163	Management of refractory angina in the contemporary era. <i>European Heart Journal</i> , 2013, 34, 2655-2657.	1.0	18
164	Synthesis and Oxidation Catalysis of [Tris(oxazoliny)borato]cobalt(II) Scorpionates. <i>European Journal of Inorganic Chemistry</i> , 2016, 2016, 2486-2494.	1.0	18
165	A monoanionic NNNN-type macrocyclic ligand for electropositive metal centers. <i>Chemical Communications</i> , 2018, 54, 2701-2714.	2.2	18
166	P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials. <i>European Heart Journal Open</i> , 2022, 2, .	0.9	18
167	The role of low-molecular-weight heparin in cardiovascular diseases. <i>Progress in Cardiovascular Diseases</i> , 2002, 45, 139-156.	1.6	17
168	Impact of extracardiac vascular disease on acute prognosis in patients who undergo percutaneous coronary interventions (data from the Blue Cross & Blue Shield of Michigan Cardiovascular) <i>Tj ETQq0 0 0 rgBT /Ovedack 10 Tf50 537 T</i>		
169	Variation in Outcomes after Percutaneous Coronary Intervention in the United States and Predictors of Periprocedural Mortality. <i>Cardiology</i> , 2005, 103, 143-147.	0.6	17
170	Meta-Analysis of Drug-Eluting Stents Versus Coronary Artery Bypass Grafting in Unprotected Left Main Coronary Artery Narrowing. <i>American Journal of Cardiology</i> , 2017, 119, 1746-1752.	0.7	17
171	Treatment-risk paradox in acute coronary syndromes. <i>European Heart Journal</i> , 2018, 39, 3807-3809.	1.0	17
172	Gamut of Cardiac Manifestations and Complications of COVID-19: A Contemporary Review. <i>Journal of Investigative Medicine</i> , 2020, 68, 1334-1340.	0.7	17
173	Current role of emboli protection devices in percutaneous coronary and vascular interventions. <i>American Heart Journal</i> , 2009, 157, 263-270.	1.2	16
174	Peripheral Arterial Disease. <i>Angiology</i> , 2013, 64, 569-571.	0.8	16
175	Portopulmonary hypertension: An update. <i>Respirology</i> , 2015, 20, 235-242.	1.3	16
176	Role of Vasodilator Testing in Pulmonary Hypertension. <i>Progress in Cardiovascular Diseases</i> , 2016, 58, 425-433.	1.6	16
177	Risk of contrast-induced acute kidney injury in ST-elevation myocardial infarction patients undergoing multi-vessel intervention—a meta-analysis of randomized trials and risk prediction modeling study using observational data. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 205-212.	0.7	16
178	Safety and efficacy of vorapaxar in secondary prevention of atherosclerotic disease: A meta-analysis of randomized control trials. <i>International Journal of Cardiology</i> , 2017, 227, 617-624.	0.8	16
179	Strength of Evidence Underlying the American Heart Association/American College of Cardiology Guidelines on Endovascular and Surgical Treatment of Peripheral Vascular Disease. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007244.	1.4	16
180	Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs?. <i>Thrombosis and Haemostasis</i> , 2006, 96, 407-412.	1.8	15

#	ARTICLE	IF	CITATIONS
181	Anodic electrochemistry of Mn and Re tricarbonyl complexes of tris(oxazoliny)phenyl borate ligands: comparison to tris(pyrazoly) borate complexes. <i>New Journal of Chemistry</i> , 2011, 35, 2169.	1.4	15
182	PAR-1 antagonists: current state of evidence. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 35, 1-9.	1.0	15
183	Antioxidants in the Practice of Medicine; What Should the Clinician Know?. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2016, 16, 13-20.	0.2	15
184	Etiologies, trends, and predictors of readmission in ST-segment elevation myocardial infarction patients undergoing multivessel percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 905-914.	0.7	15
185	Association between tumor mutation profile and clinical outcomes among Hispanic Latina women with triple-negative breast cancer. <i>PLoS ONE</i> , 2020, 15, e0238262.	1.1	15
186	Coronary Calcium Risk Score and Cardiovascular Risk. <i>Current Vascular Pharmacology</i> , 2020, 19, 280-284.	0.8	15
187	Drug-drug interactions involving antiplatelet agents. <i>European Heart Journal</i> , 2003, 24, 1707-1709.	1.0	14
188	Effectiveness of PCI for non-acute coronary artery disease. <i>Lancet, The</i> , 2009, 373, 870-872.	6.3	14
189	Role of Baseline Echocardiography in Preoperative Management of Liver Transplant Candidates. <i>American Journal of Cardiology</i> , 2013, 111, 1231.	0.7	14
190	Brugada Phenocopy in Concomitant Ethanol and Heroin Overdose. , 2015, 20, 87-90.		14
191	Duration of Dual Antiplatelet Therapy Following Drug-Eluting Stent Implantation in Diabetic and Non-Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 500-507.	1.6	14
192	Intervention strategies for multi-vessel disease in patients with ST-segment elevation myocardial infarction: A meta-analysis of randomized trials. <i>International Journal of Cardiology</i> , 2015, 179, 225-227.	0.8	13
193	Potential role of systemic thrombolysis in acute submassive intermediate risk pulmonary embolism: review and future perspectives. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2016, 10, 103-110.	1.0	13
194	Zinc Dihydride and Mixed Halo Hydrides Supported by an N-Heterocyclic Carbene. <i>European Journal of Inorganic Chemistry</i> , 2018, 2018, 1114-1119.	1.0	13
195	Atherogenic Vascular Stiffness and Hypertension. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 919.	3.8	12
196	Meta-analysis of risk of stroke and thrombo-embolism with rivaroxaban versus vitamin K antagonists in ablation and cardioversion of atrial fibrillation. <i>International Journal of Cardiology</i> , 2015, 187, 345-353.	0.8	12
197	Group 2 metal (Mg, Ca, Sr) silylamides supported by a cyclen-derived macrocyclic polyamine. <i>Dalton Transactions</i> , 2017, 46, 8451-8457.	1.6	12
198	Meta-analysis of clopidogrel pretreatment in acute coronary syndrome patients undergoing invasive strategy. <i>International Journal of Cardiology</i> , 2017, 229, 82-89.	0.8	12

#	ARTICLE	IF	CITATIONS
199	Ultrasound-Assisted Catheter-Directed Thrombolysis: A Novel and Promising Endovascular Therapeutic Modality for Intermediate-Risk Pulmonary Embolism. <i>Angiology</i> , 2017, 68, 494-501.	0.8	12
200	SCAI publications committee manual of standard operating procedures. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 145-155.	0.7	12
201	Associations between Combined Influenza and Pneumococcal Pneumonia Vaccination and Cardiovascular Outcomes. <i>Cardiology</i> , 2021, 146, 772-780.	0.6	12
202	Liver abnormalities in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2021, 11, 1-12.	0.8	12
203	Extracranial Vertebral Artery Intervention. <i>Journal of Interventional Cardiology</i> , 2007, 20, 409-416.	0.5	11
204	Nonsteroidal Anti-Inflammatory Drugs and the Heart: What Is the Danger?. <i>Congestive Heart Failure</i> , 2008, 14, 75-82.	2.0	11
205	2012 American college of cardiology foundation/society for cardiovascular angiography and interventions expert consensus document on cardiac catheterization laboratory standards update: American college of cardiology foundation task force on expert consensus documents society of thoracic surgeons society for vascular medicine. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 527-49.	0.7	11
206	Unexpected alkane elimination from cationic group 13 dialkyls in a reaction with a macrocyclic polyamine. <i>Dalton Transactions</i> , 2017, 46, 651-655.	1.6	11
207	Safety and efficacy of radial versus femoral access for rotational Atherectomy: A systematic review and meta-analysis. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 241-247.	0.3	11
208	Outcomes of rotational atherectomy versus orbital atherectomy for the treatment of heavily calcified coronary stenosis: A systematic review and meta-analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 884-892.	0.7	11
209	Comparison of Patients Undergoing Percutaneous Coronary Intervention in Contemporary U.S. Practice With ISCHEMIA Trial Population. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 2344-2349.	1.1	11
210	Outcome of acute myocardial infarction in patients with prior coronary artery bypass grafting treated with combination reduced fibrinolytic therapy and abciximab. <i>American Journal of Cardiology</i> , 2002, 90, 1198-1203.	0.7	10
211	Pharmaceutical advertising versus research spending: are profits more important than patients?. <i>American Heart Journal</i> , 2003, 146, 563-564.	1.2	10
212	Hormone Replacement Therapy and Secondary Cardiovascular Prevention: A Meta-Analysis of Randomized Trials. <i>Cardiology</i> , 2005, 104, 143-147.	0.6	10
213	Optimal platelet inhibition in patients undergoing PCI: Data from the Multicenter Registry of High-Risk Percutaneous Coronary Intervention and Adequate Platelet Inhibition (MR PCI) study. <i>American Heart Journal</i> , 2007, 154, 344.e1-344.e5.	1.2	10
214	Acute Coronary Syndromes: Unstable Angina/Non-ST Elevation Myocardial Infarction. <i>Critical Care Clinics</i> , 2007, 23, 709-735.	1.0	10
215	Effectiveness of Drug-Eluting Stents in Real-World Patients. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 454-5.	3.8	10
216	Risk Factors in First Presentation Acute Coronary Syndromes (ACS): How Do We Move From Population to Individualized Risk Prediction?. <i>Angiology</i> , 2009, 60, 663-667.	0.8	10

#	ARTICLE	IF	CITATIONS
217	Applications of monitoring platelet glycoprotein IIb/IIIa antagonism and low molecular weight heparins in cardiovascular medicine. <i>American Heart Journal</i> , 2000, 140, S136-S142.	1.2	9
218	Glycoprotein IIb/IIIa Receptor Inhibitors in 2008: Do They Still Have a Role?. <i>Journal of Interventional Cardiology</i> , 2008, 21, 118-121.	0.5	9
219	Contemporary Management of Infrapopliteal Peripheral Arterial Disease. <i>Angiology</i> , 2011, 62, 490-499.	0.8	9
220	Developing an action plan for patient radiation safety in adult cardiovascular medicine. <i>Journal of Nuclear Cardiology</i> , 2012, 19, 534-550.	1.4	9
221	Interrelationship between Chronic Kidney Disease and Risk of Cardiovascular Diseases. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2013, 11, 38-43.	0.4	9
222	Mortality and major adverse cardiovascular events after transcatheter aortic valve replacement using Edwards valve versus CoreValve: A meta-analysis. <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 24-33.	0.3	9
223	Entresto, a New Panacea for Heart Failure?. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2018, 16, 5-11.	0.4	9
224	Pulmonary Embolism Response Teams: Pursuing Excellence in the Care for Venous Thromboembolism. <i>Archives of Medical Research</i> , 2019, 50, 257-258.	1.5	9
225	In AF with recent ACS or PCI, apixaban reduced bleeding vs VKAs; aspirin increased bleeding vs placebo. <i>Annals of Internal Medicine</i> , 2019, 171, JC7.	2.0	9
226	Coronary Revascularization in the United States—Patient Characteristics and Outcomes in 2020. <i>JAMA Network Open</i> , 2020, 3, e1921322.	2.8	9
227	Congenital Absence of Left Circumflex Presenting After an Emotional Stressor. <i>Polski Przegląd Radiologii i Medycyny Nuklearnej</i> , 2015, 80, 529-531.	1.0	9
228	Current clinical perspectives on myocardial angiogenesis. <i>Molecular and Cellular Biochemistry</i> , 2004, 264, 157-167.	1.4	8
229	Brachytherapy for In-Stent Restenosis. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 1307.	3.8	8
230	Role of Oral Factor Xa Inhibitors after Acute Coronary Syndrome. <i>Cardiology</i> , 2014, 129, 224-232.	0.6	8
231	Glucose Levels and Depression in Hispanic Patients Admitted to the Cardiovascular Intensive Care Unit. <i>Angiology</i> , 2015, 66, 57-64.	0.8	8
232	Duration of dual antiplatelet therapy after various drug-eluting stent implantation. <i>International Journal of Cardiology</i> , 2016, 215, 157-166.	0.8	8
233	Facile ring-opening of THF at a lithium center induced by a pendant Si—H bond and BPh ₃ . <i>Dalton Transactions</i> , 2017, 46, 8017-8021.	1.6	8
234	Mononuclear Alkali Metal Organoperoxides Stabilized by an NNNN—Macrocycle and Short Hydrogen Bonds from ROOH Molecules. <i>Chemistry - A European Journal</i> , 2017, 23, 17213-17216.	1.7	8

#	ARTICLE	IF	CITATIONS
235	Pulmonary embolism response teams in the challenging era of venous thromboembolism associated with COVID-19. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2020, 8, 898-899.	0.9	8
236	Pulmonary Hypertension secondary to Left Heart Disease. <i>Current Vascular Pharmacology</i> , 2018, 16, 555-560.	0.8	8
237	Percutaneous treatment for carotid stenosis. <i>Cardiology Clinics</i> , 2002, 20, 589-597.	0.9	7
238	Clinical Association between Renal Insufficiency and Positive Troponin I in Patients with Acute Coronary Syndrome. <i>Cardiology</i> , 2004, 102, 215-219.	0.6	7
239	Elective coronary revascularization, an iatrogenic form of acute coronary syndrome: How can clinicians reduce the risks?. <i>American Heart Journal</i> , 2004, 148, 371-377.	1.2	7
240	Current strategies with high-dose tirofiban. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007, 3, 275-280.	1.5	7
241	Reperfusion Strategies for Acute Ischemic Stroke. <i>Angiology</i> , 2012, 63, 289-296.	0.8	7
242	Depression as a Predictor of Length of Stay in Patients Admitted to the Cardiovascular Intensive Care Unit at a University Medical Center. <i>Angiology</i> , 2014, 65, 580-584.	0.8	7
243	Obesity Paradox in Contemporary Cardiology Practice. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1293-1294.	1.1	7
244	SCAI/ACVP expert consensus statement on cardiovascular catheterization laboratory economics: If the cath lab is your home you should understand its finances. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 123-135.	0.7	7
245	Pulmonary embolism response teams: Purpose, evidence for efficacy, and future research directions. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 769.	1.0	7
246	Percutaneous Closure of Patent Foramen Ovale in Patients with Cryptogenic Stroke – An Updated Comprehensive Meta-Analysis. <i>Cardiovascular Revascularization Medicine</i> , 2019, 20, 687-694.	0.3	7
247	Thromboembolic Complications in Severe COVID-19: Current Antithrombotic Strategies and Future Perspectives. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2021, 21, 23-29.	0.2	7
248	Clinical application of procedural platelet monitoring during percutaneous coronary intervention among patients at increased bleeding risk. <i>Journal of Thrombosis and Thrombolysis</i> , 2001, 11, 151-154.	1.0	6
249	Optimal treatment for in-stent restenosis after BMS-DES, coated balloon, or scalpel?. <i>European Heart Journal</i> , 2008, 29, 1595-1596.	1.0	6
250	Emerging P2Y12 Receptor Antagonists: Role in Coronary Artery Disease. <i>Current Vascular Pharmacology</i> , 2010, 8, 93-101.	0.8	6
251	Evidence-based management of carotid artery disease. <i>International Journal of Angiology</i> , 2010, 19, e21-e24.	0.2	6
252	Current Management of Peripheral Vascular Disease: Where is the Evidence?. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2011, 9, 128-136.	0.4	6

#	ARTICLE	IF	CITATIONS
253	Implementation of Evidence-Based Therapies for Myocardial Infarction and Survival. JAMA - Journal of the American Medical Association, 2011, 305, 1710.	3.8	6
254	Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients With and Without Acute Coronary Syndrome. Mayo Clinic Proceedings, 2016, 91, 1084-1093.	1.4	6
255	Culprit Vessel Only Versus Multivessel Percutaneous Coronary Intervention in Acute Myocardial Infarction with Cardiogenic Shock: A Systematic Review and Meta-Analysis. Cardiovascular Revascularization Medicine, 2019, 20, 956-964.	0.3	6
256	Perioperative Acute Pulmonary Embolism: A Concise Review with Emphasis on Multidisciplinary Approach. International Journal of Angiology, 2020, 29, 183-188.	0.2	6
257	Direct oral anticoagulants in chronic thromboembolic pulmonary hypertension. Journal of Thrombosis and Thrombolysis, 2021, 52, 791-796.	1.0	6
258	Lack of Cardioprotective Effect of Naproxen. Archives of Internal Medicine, 2002, 162, 2637-2637.	4.3	6
259	Management of Chronic Total Occlusion of Coronary Artery. International Journal of Angiology, 2021, 30, 048-052.	0.2	6
260	Current Evidence for Antithrombotic Therapy after Peripheral Vascular Interventions. Current Vascular Pharmacology, 2013, 11, 507-513.	0.8	6
261	A Review of the Current Role of Blood Clotting Analyzers in Clinical Practice. Cardiovascular & Hematological Disorders Drug Targets, 2018, 17, 167-179.	0.2	6
262	Developing an Action Plan for Patient Radiation Safety in Adult Cardiovascular Medicine. Circulation: Cardiovascular Imaging, 2012, 5, 400-414.	1.3	5
263	Successful pharmacomechanical intervention with ultrasonic-accelerated thrombolytic catheter for massive pulmonary embolism. Indian Heart Journal, 2013, 65, 699-702.	0.2	5
264	SCAI/AATS/ACC/STS Operator and Institutional Requirements for Transcatheter Valve Repair and Replacement: Part II. Mitral Valve. Annals of Thoracic Surgery, 2014, 98, 765-777.	0.7	5
265	Double right coronary artery and its clinical significance: Review of the literature. Cardiovascular Revascularization Medicine, 2017, 18, 632-635.	0.3	5
266	Guide of Hypertensive Crisis Pharmacotherapy. Cardiovascular & Hematological Disorders Drug Targets, 2017, 17, 52-57.	0.2	5
267	Hyridoaluminates and hydridoborates of lithium stabilized by a Cyclen-derived NNNN-Type macrocyclic ligand. Journal of Organometallic Chemistry, 2019, 894, 39-42.	0.8	5
268	Minimizing Distal Embolization During Carotid Artery Stenting. JACC: Cardiovascular Interventions, 2019, 12, 404-405.	1.1	5
269	Ein maskiertes Kupferhydrid als Katalysator für die Carbonylhydrosilylierung in wässrigen Lösungen. Angewandte Chemie, 2019, 131, 1832-1836.	1.6	5
270	Drug-Eluting Versus Bare Metal Stents in Saphenous Vein Graft Intervention: An Updated Comprehensive Meta-Analysis of Randomized Trials. Cardiovascular Revascularization Medicine, 2019, 20, 758-767.	0.3	5

#	ARTICLE	IF	CITATIONS
271	Outcomes of Percutaneous Coronary Intervention Versus Optimal Medical Treatment for Chronic Total Occlusion: A Comprehensive Meta-analysis. <i>Current Problems in Cardiology</i> , 2021, 46, 100695.	1.1	5
272	Effect of Mineralocorticoid Receptor Antagonists in Heart Failure with Preserved Ejection Fraction and with Reduced Ejection Fraction - A Narrative Review. <i>Current Vascular Pharmacology</i> , 2022, 20, 46-51.	0.8	5
273	Impact of Chronic Kidney Disease on Revascularization and Outcomes in Patients with ST-Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2021, 150, 15-23.	0.7	5
274	Review of Newer Anticoagulants and Anti-platelet Agents in Acute Coronary Syndrome and Cardiovascular Diseases. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2014, 11, 194-202.	0.4	5
275	Cyclopentadienyl Complexes of the Alkaline Earths in Light of the Periodic Trends. <i>Chemistry - an Asian Journal</i> , 2022, 17, .	1.7	5
276	Renal artery stenosis: who to screen and how to treat?. <i>ACC Current Journal Review</i> , 2003, 12, 70-75.	0.1	4
277	Optimizing management of patients with coronary artery disease: how do we get there?The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.. <i>European Heart Journal</i> , 2005, 26, 1147-1149.	1.0	4
278	Optimal Management of Hypertension in patients with Ischemic Heart Disease. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2009, 7, 198-205.	0.4	4
279	Natural History of Saphenous Vein Grafts. <i>Interventional Cardiology Clinics</i> , 2013, 2, 251-258.	0.2	4
280	Prevalence and Predictors of Left Ventricular Diastolic Dysfunction in a Hispanic Patient Population. <i>International Journal of Angiology</i> , 2013, 22, 229-234.	0.2	4
281	SCAI/AATS/ACC/STS operator and institutional requirements for transcatheter valve repair and replacement. Part II. Mitral valve. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 84, 567-580.	0.7	4
282	Cardiopulmonary hemodynamics for accurate diagnosis of portopulmonary hypertension: A redefinition to consider. <i>Hepatology</i> , 2015, 61, 733-734.	3.6	4
283	SCAI/AATS/ACC/STS operator and institutional requirements for transcatheter valve repair and replacement, Part III: Pulmonic valve. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 85-93.	0.7	4
284	Antithrombotic therapy before, during and after transcatheter aortic valve replacement (TAVR). <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 467-473.	1.0	4
285	Is multivessel intervention in ST-elevation myocardial infarction associated with early harm? Insights from observational data. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 697-707.	0.7	4
286	Paclitaxel-Coated Balloons: Review of a Promising Interventional Approach to Preventing Restenosis in Femoropopliteal Arteries. <i>International Journal of Angiology</i> , 2016, 25, 075-080.	0.2	4
287	Current Trends and Future Perspectives in the Treatment of Pulmonary Arterial Hypertension. <i>Current Problems in Cardiology</i> , 2018, 43, 191-216.	1.1	4
288	Clinical characteristics and outcomes of patients requiring prolonged inotropes after left ventricular assist device implantation. <i>Artificial Organs</i> , 2020, 44, E382-E393.	1.0	4

#	ARTICLE	IF	CITATIONS
289	Early Post-Percutaneous Coronary Intervention Chest Pain: A Nationwide Survey on Interventional Cardiologists' Perspective. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1517-1522.	0.3	4
290	Management of Cocaine-Associated Non-â€œST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 637-638.	1.1	4
291	Impact and Role of Pulmonary Embolism Response Teams in Venous Thromboembolism Associated with Covid-19. <i>Journal of Investigative Medicine</i> , 2021, 69, 1153-1155.	0.7	4
292	Sodium-Glucose Cotransporter Inhibitors in Non- Diabetic Heart Failure: A Narrative Review. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2021, 21, 1-6.	0.2	4
293	The Role of Percutaneous Coronary Intervention in the Treatment of Chronic Total Occlusions: Rationale and Review of the Literature. <i>Current Vascular Pharmacology</i> , 2019, 17, 278-290.	0.8	4
294	Optimal Medical Therapy for Coronary Artery Disease in 2011 â€œ Perspectives from the STICH Trial. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2011, 9, 269-276.	0.4	4
295	Contemporary Review of Drugs Used to Treat Obesity. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2014, 11, 272-280.	0.4	4
296	Heart Failure with Preserved Ejection Fraction: Entresto a Possible Option. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2017, 17, 80-85.	0.2	4
297	Current Role of Antithrombotic Agents in the Treatment of Acute Coronary Syndromes. <i>Seminars in Thrombosis and Hemostasis</i> , 2004, 30, 627-632.	1.5	3
298	The Use of Antithrombotics for Acute Coronary Syndromes in the Emergency Department: Considerations and Impact. <i>Progress in Cardiovascular Diseases</i> , 2007, 50, 167-180.	1.6	3
299	Current Endovascular Treatment of Peripheral Arterial Disease. <i>Progress in Cardiovascular Nursing</i> , 2007, 22, 31-37.	0.5	3
300	Platelet glycoprotein IIb/IIIa receptor inhibitors--end of an era?. <i>European Heart Journal</i> , 2008, 29, 429-431.	1.0	3
301	Current Status of Carotid Stenting. <i>Current Vascular Pharmacology</i> , 2008, 6, 143-147.	0.8	3
302	Chronic total occlusions in non-infarct-related arteries. <i>European Heart Journal</i> , 2012, 33, 695-697.	1.0	3
303	Clinical profiles and outcomes of acute aortic dissection in a predominantly Hispanic population. <i>Medical Science Monitor</i> , 2014, 20, 747-751.	0.5	3
304	SCAI/AATS/ACC/STS operator and institutional requirements for transcatheter valve repair and replacement. Part II. Mitral valve. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2014, 148, 387-400.	0.4	3
305	Effect of cardiac resynchronization therapy on right ventricular function. <i>International Journal of Cardiology</i> , 2016, 209, 34-36.	0.8	3
306	Incidence of Renal Failure Requiring Hemodialysis Following Transcatheter Aortic Valve Replacement. <i>American Journal of the Medical Sciences</i> , 2016, 352, 306-313.	0.4	3

#	ARTICLE	IF	CITATIONS
307	Valvular performance and aortic regurgitation following transcatheter aortic valve replacement using Edwards valve versus CoreValve for severe aortic stenosis: A Meta-analysis. <i>Cardiovascular Revascularization Medicine</i> , 2016, 17, 248-255.	0.3	3
308	Current Trends and Future Perspectives in the Treatment of Pulmonary Hypertension: WHO Group II-V. <i>Current Problems in Cardiology</i> , 2018, 43, 217-231.	1.1	3
309	Coronary lesion complexity and the benefit of potent platelet inhibition after percutaneous coronary intervention. <i>European Heart Journal</i> , 2018, 39, 4122-4124.	1.0	3
310	Bivalirudin Versus Heparin During Intervention in Acute Coronary Syndrome: A Systematic Review of Randomized Trials. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2020, 20, 3-15.	0.2	3
311	After revascularization for PAD, rivaroxaban reduced vascular events with a small increase in major bleeding. <i>Annals of Internal Medicine</i> , 2020, 173, JC22.	2.0	3
312	High Flow Nasal Cannula Oxygenation Successfully Used as Bridge Therapy for Systemic Thrombolysis in COVID-19 Associated Intermediate-high Risk Pulmonary Embolism. <i>Current Problems in Cardiology</i> , 2022, 47, 101000.	1.1	3
313	Red Blood Cell Transfusion Trigger in Cardiac Disease. , 2015, , 25-34.		3
314	Reversal of Newer Direct Oral Anticoagulant Drugs (DOACs). <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2017, 14, 76-81.	0.4	3
315	Blunt Thoracic Aortic Injury and Contemporary Management Strategy. <i>Angiology</i> , 2022, 73, 497-507.	0.8	3
316	Percutaneous coronary intervention versus coronary artery bypass grafting in diabetic patients. <i>Cardiology Clinics</i> , 2005, 23, 185-191.	0.9	2
317	Pharmacotherapy of acute coronary syndrome: the ACUITY trial. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 369-380.	0.9	2
318	Contemporary Management of Hypertension - How to Optimize Therapy. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2009, 9, 181-192.	0.2	2
319	Spatial distribution of coronary artery thromboses in patients with chronic kidney disease: implications for diagnosis and treatment. <i>Kidney International</i> , 2009, 75, 7-9.	2.6	2
320	Antithrombotics and stent type for primary PCI. <i>Lancet, The</i> , 2011, 377, 2154-2156.	6.3	2
321	Current Approaches to Prevention of Contrast Induced Acute Kidney Injury. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2011, 9, 247-252.	0.4	2
322	Idarucizumab: Clinical Role of a Novel Reversal Agent for Dabigatran. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2016, 16, 25-29.	0.2	2
323	Traditional NSAIDs and coxibs: is one better than the other?. <i>European Heart Journal</i> , 2017, 38, ehw507.	1.0	2
324	Role of Vorapaxar After Coronary Revascularization. <i>American Journal of Cardiology</i> , 2016, 117, 1059-1064.	0.7	2

#	ARTICLE	IF	CITATIONS
325	One-Year Survival is Not Affected by Gastrointestinal Bleeding After Percutaneous Coronary Interventions. <i>American Journal of the Medical Sciences</i> , 2017, 353, 381-386.	0.4	2
326	Cardiovascular and Hematological Medicine in 2018 â€“ Advances and Insights. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2018, 16, 2-2.	0.4	2
327	Underutilization of Cardiac Therapies in Patients with Acute Ischemic Stroke and Elevated Troponin. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2019, 17, 144-151.	0.4	2
328	Tailoring strategies to optimize ischaemic benefit vs. bleeding risk in individuals post-myocardial infarction. <i>European Heart Journal</i> , 2020, 41, 844-846.	1.0	2
329	Updates in Anti-anginal and Anti-ischemic Therapies for Acute Coronary Syndromes. <i>Current Cardiology Reports</i> , 2020, 22, 126.	1.3	2
330	The Effect of Clinical Depression on Post-TAVI All-Cause Mortality. <i>American Journal of Cardiology</i> , 2021, 155, 151-152.	0.7	2
331	Serelaxin: New Investigational Treatment in Acute Heart Failure. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2014, 11, 243-248.	0.4	2
332	Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and LDL Lowering in the Contemporary Management of Dyslipidemia. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2014, 11, 281-288.	0.4	2
333	Coronary revascularization prior to elective vascular surgery: Does it reduce cardiac risk?. <i>Journal of Vascular Surgery</i> , 2002, 36, 644-645.	0.6	1
334	Role of Emboli protection devices in native coronary and saphenous vein graft percutaneous interventions. <i>ACC Current Journal Review</i> , 2004, 13, 32-35.	0.1	1
335	Review: aspirin reduces vascular events but increases bleeding in primary and secondary prevention. <i>Evidence-Based Medicine</i> , 2009, 14, 172-172.	0.6	1
336	Response to: Brugada Phenocopy: Morphological Classification and Importance of Provocative Testing. <i>Annals of Noninvasive Electrocardiology</i> , 2014, 19, 606-606.	0.5	1
337	SCAI/AATS/ACC/STS operator and institutional requirements for transcatheter valve repair and replacement, part III. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2015, 149, e71-e78.	0.4	1
338	SCAI/AATS/ACC/STS Operator and Institutional Requirements for Transcatheter Valve Repair and Replacement, Part III: Pulmonic Valve. <i>Annals of Thoracic Surgery</i> , 2015, 99, 1857-1864.	0.7	1
339	Myxomatous Mitral Valve with Prolapse and Flail Scallop. <i>Polski Przegląd Radiologii I Medycyny Nuklearnej</i> , 2016, 81, 233-235.	1.0	1
340	Impact of intraprocedural thrombotic events on short- and long-term outcomes following percutaneous coronary intervention. Evidence from a meta-analysis. <i>International Journal of Cardiology</i> , 2016, 202, 469-476.	0.8	1
341	Prior Coronary Revascularization and Risk of Noncardiac Surgery. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 339-341.	1.1	1
342	Cardiovascular and Hematological Medicine in 2019 â€“ Advances and Insights. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2019, 17, 2-2.	0.4	1

#	ARTICLE	IF	CITATIONS
343	Coronary Angiography Challenges After Transcatheter Aortic Valve Replacementâ€”Transcatheter Aortic Valve Replacement. <i>Journal of the American Heart Association</i> , 2020, 9, e017409.	1.6	1
344	Outcomes Following Percutaneous Coronary Intervention Before, During, and After Transition to a Default Transradial Approach at a Veterans Affairs Medical Center. <i>Angiology</i> , 2020, 71, 602-608.	0.8	1
345	Calcium, Strontium, and Barium. , 2021, , 106-138.		1
346	Hypertension in Diabetes: Optimal Pharmacotherapy. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2011, 9, 95-105.	0.4	1
347	Eisenmenger Syndrome: Recent Advances in Pharmacotherapy. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2014, 11, 289-296.	0.4	1
348	Myopericarditis as a complication of nonspecific colitis. <i>American Journal of Case Reports</i> , 2014, 15, 82-84.	0.3	1
349	Is Percutaneous Coronary Intervention Now the Default Revascularization Strategy for Unprotected Left Main Coronary Artery Stenosis?. <i>Journal of the American Heart Association</i> , 2022, 11, e025748.	1.6	1
350	Effect of uncoated stenting versus balloon angioplasty alone of long coronary (>20 mm) versus shorter narrowings on One-Year Event-Free survival. <i>American Journal of Cardiology</i> , 2003, 91, 587-590.	0.7	0
351	Current Perspectives on Hypertension in Asian Indians. <i>Current Hypertension Reviews</i> , 2007, 3, 264-269.	0.5	0
352	The Timely Coupling of Mechanical Revascularization following Thrombolysis for Myocardial Infarction. <i>Cardiology</i> , 2007, 107, 337-339.	0.6	0
353	Unraveling the Genetic Predisposition for Aortic Aneurysms: Is it Time for Tailored Medicine?. <i>American Journal of Hypertension</i> , 2008, 21, 967-967.	1.0	0
354	Antithrombotic Agents for Acute Coronary Syndromes. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2008, 6, 130-141.	0.4	0
355	Percutaneous versus surgical revascularization for symptomatic carotid artery disease. <i>Current Cardiology Reports</i> , 2009, 11, 384-390.	1.3	0
356	The high cost of nonadherence after percutaneous coronary interventionâ€”Can health care reform solve this problem?. <i>American Heart Journal</i> , 2009, 158, 506-508.	1.2	0
357	Antithrombotic Options for Atrial Fibrillation in 2012. <i>Cardiovascular & Hematological Disorders Drug Targets</i> , 2012, 12, 1-5.	0.2	0
358	Eidtorial from Editor-in-Chief : [Keeping up with Advances in Cardiovascular and Hematological Medicine in 2012]. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2012, 10, 1-1.	0.4	0
359	Perfluorooctanoic Acid Exposure and Cardiovascular Disease. <i>Archives of Internal Medicine</i> , 2012, 172, 1403.	4.3	0
360	Patient-Level vs Group-Level Data to Adjust Meta-analysis on Transfusion and Mortalityâ€”Reply. <i>JAMA Internal Medicine</i> , 2013, 173, 1157.	2.6	0

#	ARTICLE	IF	CITATIONS
361	Review: After coronary DES placement, longer vs shorter DAPT increases major bleeding and death and reduces MI. <i>Annals of Internal Medicine</i> , 2015, 163, JC6.	2.0	0
362	Reply From the Author. <i>Angiology</i> , 2015, 66, 493-493.	0.8	0
363	Reply. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2459-2460.	1.1	0
364	Current role of β -blockers after MI in patients without HF. <i>Nature Reviews Cardiology</i> , 2016, 13, 699-700.	6.1	0
365	Renal artery revascularisation: can we predict who benefits?. <i>Heart Asia</i> , 2017, 9, e010951.	1.1	0
366	A rare cause of chest pain: Cardiac synovial sarcoma. <i>Egyptian Journal of Radiology and Nuclear Medicine</i> , 2017, 48, 869-871.	0.3	0
367	Usefulness of left ventricular mass change to predict progression of renal dysfunction in Hispanics. <i>Baylor University Medical Center Proceedings</i> , 2018, 31, 20-24.	0.2	0
368	Cardiovascular and Hematological Medicine in 2020 – Advances and Insights. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2020, 18, 2-2.	0.4	0
369	Expression of Concern: Cardiac overexpression of myotrophin triggers myocardial hypertrophy and heart failure in transgenic mice.. <i>Journal of Biological Chemistry</i> , 2020, 295, 3385.	1.6	0
370	Linking the right education to right heart catheterization. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 509-510.	0.7	0
371	Is Colchicine Beneficial for the Prevention of Cardiovascular Events After Myocardial Infarction?. <i>Angiology</i> , 2021, 72, 501-502.	0.8	0
372	Effect SARS-COV-2 on Cases of Transcatheter Aortic Valve Implantation. <i>American Journal of Cardiology</i> , 2021, 151, 123-124.	0.7	0
373	Takayasu's Arteritis as a Rare Cause of Group 4 Pulmonary Hypertension. <i>Current Problems in Cardiology</i> , 2022, 47, 101008.	1.1	0
374	Sex Differences of Extracorporeal Membrane Oxygenation Distribution Among SARS-COV-2 Cases. <i>Angiology</i> , 2021, , 000331972110497.	0.8	0
375	Combination Secondary Prevention Therapies in Vascular Diseases. <i>Vascular Disease Prevention</i> , 2005, 2, 17-19.	0.2	0
376	Chest Pain. <i>JACC: Case Reports</i> , 2021, 3, 1643-1648.	0.3	0
377	Patent Foramen Ovale, the Role of Antiplatelet Therapy Alone or Anticoagulant Therapy Alone Versus Device Closure for Cryptogenic Stroke: A Review of the Literature and Current Recommendations. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2020, 18, 135-150.	0.4	0
378	The Association of N-Terminal Pro-Brain Natriuretic Peptide With Time to Clinical Worsening in Hispanic Patients With Pulmonary Arterial Hypertension. <i>Cardiology Research</i> , 2022, 13, 73-80.	0.5	0